Table 1.

Baseline Characteristics of Subjects

Characteristic	Buprenorphine Implant Group n=114	Placebo Implant Group n=54	Sublingual Buprenorphine n=119
Age, mean (SD), y	36.4 (11.0)	35.2 (10.3)	35.3 (10.9)
Male, No. (%)	72 (63.2)	31 (57.4)	72 (60.5)
Race, N (%)
White	95 (83.3)	45 (83.3)	97 (81.5)
Black	14 (12.3)	7 (13.0)	16 (13.4)
Other	5 (4.4)	2 (3.8)	6 (5.0)
Hispanic Ethnicity, N(%)	24 (21.1)	11 (20.4)	17 (14.3)
Primary opioid of abuse, N (%)
Heroin	76 (66.7)	28 (51.9)	75 (63.0)
Prescription pain med.	38 (33.3)	26 (48.1)	43 (36.1)
Other	0	0	1 (0.8)
Diagnosis of opioid dependence for > 5 years, N (%)	29 (25.4)	12 (22.2)	37 (31.1)
Previous treatment for opioid Dependence, N (%)	63 (55.3)	31 (57.4)	68 (57.1)